Inspire Veterinary Partners, Inc. (IVPR) — SEC Filings
Inspire Veterinary Partners, Inc. (IVPR) — 50 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 32 8-K, 4 S-1/A, 4 10-Q.
View Inspire Veterinary Partners, Inc. on SEC EDGAR
Overview
Inspire Veterinary Partners, Inc. (IVPR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: Inspire Veterinary Partners, Inc. entered into a Material Definitive Agreement on December 18, 2025. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The exact nature of the agreement and the details of the equity sales are not specifi
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 7 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Inspire Veterinary Partners, Inc. is neutral.
Filing Type Overview
Inspire Veterinary Partners, Inc. (IVPR) has filed 32 8-K, 4 S-1/A, 4 10-Q, 2 DEF 14A, 4 S-1, 1 10-K, 1 SC 13G/A, 1 10-Q/A, 1 SC 13G with the SEC between Jun 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IVPR's 47 recent filings, 8 were flagged as high-risk, 29 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4,316,132 |
| Net Income | -$2,526,273 |
| EPS | -$0.41 |
| Debt-to-Equity | N/A |
| Cash Position | $341,746 |
| Operating Margin | N/A |
| Total Assets | $23,955,766 |
| Total Debt | $19,787,085 |
Key Executives
- Kimball Carr
- Sean Klein
- Richard Frank
- Sean J. Klein, Esq.
- M. Ali Panjwani, Esq.
- Mark E. Crone, Esq.
- Ross D. Carmel, Esq.
- Dr. Robert J. Costello
- Ms. Jennifer L. Smith
- Dr. Robert J. Smith
- Ms. Sarah Chen
- Joe Laxa
Industry Context
The veterinary services industry is generally considered stable, driven by consistent demand for pet care. However, the market is becoming increasingly consolidated with large corporate consolidators acquiring independent practices. Companies like Inspire Veterinary Partners operate within this evolving landscape, facing competition from both independent clinics and larger groups.
Top Tags
material-agreement (12) · Veterinary Services (7) · equity-sale (6) · filing (5) · corporate-action (4) · ipo (4) · sec-filing (4) · 8-k (3) · Private Placement (3) · delisting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Class A Common Stock offered by Selling Stockholders | 46,419,092 shares | Represents potential dilution for existing shareholders |
| Last reported sale price of Common Stock | $0.12 | On November 28, 2025, contributing to Nasdaq delisting |
| Class A common stock outstanding immediately prior to this offering | 38,567,465 shares | Baseline for calculating potential dilution |
| Class A common stock outstanding immediately after this offering | 84,986,557 shares | Total shares after potential conversion and exercise by selling stockholders |
| Exercise price of warrants | $1.00 | For 7,725,000 shares issued to Private Placement investors |
| Aggregate principal amount of promissory notes | $1,250,000 | Issued to Target Capital 1, LLC, convertible into 12,500,000 shares |
| Series B Preferred Stock redeemed | 2,027 shares | For approximately $2.7 million on December 1, 2025 |
| Total principal amount of Senior Convertible Promissory Notes | $357,142.86 | Issued to Keystone Capital Partners, LLC and Seven Knots, LLC on November 5, 2025 |
| Interest rate on Senior Convertible Promissory Notes | 10% | Payable monthly, maturing August 5, 2026 |
| Conversion price discount for Senior Convertible Promissory Notes | 90% | Of the lowest sale price over 20 consecutive trading days |
| Net Loss (Q3 2025) | $2.53M | Reduced from $3.49M in Q3 2024, showing improvement. |
| Total Revenue (Q3 2025) | $4.32M | Increased from $4.05M in Q3 2024, indicating quarterly growth. |
| Total Revenue (YTD Q3 2025) | $12.24M | Decreased from $13.27M in YTD Q3 2024, showing year-to-date decline. |
| Accumulated Deficit | $44.33M | Increased from $36.35M at Dec 31, 2024, highlighting ongoing losses. |
| Net Loss Per Share (Q3 2025) | $0.41 | Improved from $0.85 in Q3 2024, despite increased shares outstanding. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Inspire Veterinary Partners, Inc. (IVPR)?
Inspire Veterinary Partners, Inc. has 50 recent SEC filings from Jun 2024 to Dec 2025, including 32 8-K, 4 S-1/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IVPR filings?
Across 50 filings, the sentiment breakdown is: 7 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Inspire Veterinary Partners, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Inspire Veterinary Partners, Inc. (IVPR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Inspire Veterinary Partners, Inc.?
Key financial highlights from Inspire Veterinary Partners, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IVPR?
The investment thesis for IVPR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Inspire Veterinary Partners, Inc.?
Key executives identified across Inspire Veterinary Partners, Inc.'s filings include Kimball Carr, Sean Klein, Richard Frank, Sean J. Klein, Esq., M. Ali Panjwani, Esq. and 7 others.
What are the main risk factors for Inspire Veterinary Partners, Inc. stock?
Of IVPR's 47 assessed filings, 8 were flagged high-risk, 29 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Inspire Veterinary Partners, Inc.?
Forward guidance and predictions for Inspire Veterinary Partners, Inc. are extracted from SEC filings as they are enriched.